An in Vitro Assay of hERG K+ Channel Potency for a New EGFR Inhibitor FHND004
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2018.00577
Abstract: FHND004 is a newly synthesized epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer (NSCLC). The aim of the present study was to investigate the impacts of FHND004 on human… read more here.
Keywords: egfr inhibitor; potency; herg; fhnd004 ... See more keywords